According to Asia Scientific Global, the FDA has cleared an IND that will allow a Phase 1 trial of its Beta1 inhaled dry powder therapy for the treatment of erectile dysfunction to move forward, and the company now plans to initiate the trial by mid-2026. ASG announced in February 2025 that it had held a pre-IND meeting with the agency regarding Beta1.
The company said, “Receiving FDA IND clearance positions Beta1 as a potential next-generation therapeutic option for erectile dysfunction. . . .This event marks a key milestone in ASG’s new drug development efforts. It not only affirms the Company’s R&D capabilities but also significantly enhances its visibility in the global market. “
Read the Asia Scientific Global press release
